

Description of Additional Supplementary Files

Supplementary Data 1: Medicines included in the definition of Any anti-seizure medicine (ASM).

Supplementary Data 2: Derivation of variable indicating maternal chronic comorbidity (ICD10).

Supplementary Data 3: Derivation of variables reflecting presence of a condition indicating anti-seizure medicine (ASM) exposure (ICD10).

Supplementary Data 4: Derivation of variable indicating maternal alcohol and drug misuse (ICD10).

Supplementary Data 5: Derivation of covariates reflecting presence of a condition indicating anti-seizure medicine (ASM) exposure (prescription).

Supplementary Data 6: Characteristics of singleton pregnancies by exposure to selected anti-seizure medicine (ASM) monotherapy.

Supplementary Data 7: Characteristics of singleton pregnancies conceived in Scotland between 1 April 2010 and 2 July 2023 (pregnancy cohort).

Supplementary Data 8: Characteristics of live-born babies from singleton pregnancies conceived in Scotland between 1 April 2010 and 1 July 2020 (live birth cohort).

Supplementary Data 9: Outcomes in exposed and matched unexposed groups.

Supplementary Data 10: Distribution of types of pregnancy loss among anti-seizure medicine (ASM) exposed and matched unexposed singleton pregnancies in pregnancy cohort.

Supplementary Data 11: Outcomes in exposed and matched unexposed groups.

Supplementary Data 12: Outcomes in exposed and matched unexposed groups.

Supplementary Data 13: Odds ratios for interaction between maternal receipt of high dose folic acid and ASM exposure.

Supplementary Data 14: Outcomes in exposed and matched unexposed groups.

Supplementary Data 15: Odds ratios from conditional multinomial logistic regression models for the association between exposure to anti-seizure medicine (ASM) during pregnancy and type of pregnancy loss.

Supplementary Data 16: Distribution of types of congenital conditions among babies exposed to anti-seizure medicines (ASMs) and matched unexposed babies from singleton pregnancies in baby cohort.

Supplementary Data 17: Outcomes in exposed and matched unexposed groups.

Supplementary Data 18: Distribution of types of early childhood developmental concerns among live-born babies exposed to anti-seizure medicines (ASM) and matched unexposed live births from singleton pregnancies in live birth cohort.